<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Abstract" exact="Antibody" post="immunotherapy is revolutionizing modern medicine. The field has advanced"/>
 <result pre="and distribution. Some of these hurdles may be overcome through" exact="transient" post="in vivo gene delivery platforms, such as non-viral synthetic"/>
 <result pre="vivo expression and having an impact in animal models of" exact="infectious diseases" post="and cancer, among others. Funding http://dx.doi.org/10.13039/100000865Bill and Melinda Gates"/>
 <result pre="have made significant progress and are demonstrating promising efficacy in" exact="infectious disease" post="and cancer studies in small and large animal models."/>
 <result pre="made significant progress and are demonstrating promising efficacy in infectious" exact="disease" post="and cancer studies in small and large animal models."/>
 <result pre="progress and are demonstrating promising efficacy in infectious disease and" exact="cancer" post="studies in small and large animal models. These platforms"/>
 <result pre="represent different strategies for deployment, with unique advantages and challenges." exact="Antibody" post="Therapy Monoclonal antibody (mAb) therapy has changed the landscape"/>
 <result pre="Administration (FDA) and European Medicines Agency (EMA) for treatment of" exact="infectious diseases," post="cancer, asthma, and autoimmunity, among others. With these successes,"/>
 <result pre="and costs of administration. Subcutaneous (SC) delivery has advantages for" exact="lower" post="dose antibody delivery, including being less invasive and the"/>
 <result pre="and the possibility for self-administration in several indications, such as" exact="rheumatoid arthritis," post="primary immunodeficiencies, and multiple sclerosis [10, 11]. Drug autoinjectors"/>
 <result pre="possibility for self-administration in several indications, such as rheumatoid arthritis," exact="primary" post="immunodeficiencies, and multiple sclerosis [10, 11]. Drug autoinjectors have"/>
 <result pre="in several indications, such as rheumatoid arthritis, primary immunodeficiencies, and" exact="multiple sclerosis" post="[10, 11]. Drug autoinjectors have greatly improved the uptake"/>
 <result pre="As a result, the mAb may be eliminated before reaching" exact="systemic" post="circulation (reviewed in Ref. [13]). Nonetheless, the impact and"/>
 <result pre="[13]). Nonetheless, the impact and importance of mAbs on human" exact="disease" post="and the growth in new applications of such technology"/>
 <result pre="options for this growing class of important biologics. In Vivo" exact="Antibody" post="Gene Delivery In vivo gene-encoded antibody delivery is an"/>
 <result pre="for in vivo delivery. Historically, in the gene therapy arena," exact="viral" post="vectors [adeno-associated virus (AAV) is the current favored viral"/>
 <result pre="arena, viral vectors [adeno-associated virus (AAV) is the current favored" exact="viral" post="vector] have been promising for in vivo transfection and"/>
 <result pre="vivo transfected targeted cells, followed by antibody secretion into the" exact="systemic" post="circulation. RNA approaches use LNP to allow for delivery"/>
 <result pre="summary of synthetic DNA and synthetic mRNA and comparison with" exact="viral" post="vector delivery platforms for in vivo mAb delivery is"/>
 <result pre="different in vivo antibody gene delivery platforms Synthetic DNA mRNA" exact="Viral" post="vector Starting material Plasmid DNA Plasmid DNA Plasmid DNA"/>
 <result pre="vector In vivo product mAb, BsMAb mAb, BsMAb mAb, BsMAb" exact="Transient" post="Yes Yes Yes; however, rare cases may integrate (AAV)"/>
 <result pre="IV, IM/ID IM, IN, IV, IC, IO, IT Tissue specificity/tropism" exact="Local" post="site of administration Non-specific Serotype dependent Vector take High"/>
 <result pre="mAb monoclonal antibody, mRNA messenger RNA, SAEs serious adverse events" exact="Viral" post="Vector-Encoded Antibodies The original studies surrounding in vivo antibody"/>
 <result pre="antibody gene delivery focused primarily on gene delivery using recombinant" exact="viral" post="vectors such as AAV and adenovirus (Ad), which were"/>
 <result pre="is more immune silent as a vector compared with other" exact="viral" post="vector platforms and can achieve long persistence of the"/>
 <result pre="genetic cassette with a single administration (reviewed in Ref. [16])." exact="Viral" post="vector delivery is dependent on viral surface receptor-mediated entry"/>
 <result pre="(reviewed in Ref. [16]). Viral vector delivery is dependent on" exact="viral" post="surface receptor-mediated entry into cells, with different vectors displaying"/>
 <result pre="capsid (AAV) [17] or hexon (Ad) [18] proteins. In vivo" exact="viral" post="vectors encoding antibody genes have been reported to be"/>
 <result pre="or systemically via IV or intrathecal (IT) routes, leading to" exact="viral infection" post="with production of the virus-encoded antibody predominately from liver"/>
 <result pre="systemically via IV or intrathecal (IT) routes, leading to viral" exact="infection" post="with production of the virus-encoded antibody predominately from liver"/>
 <result pre="an Ad vector-encoded antibody followed by an AAV-encoded mAb targeting" exact="anthrax" post="and demonstrated successful rapid and long-lasting expression [20]. Around"/>
 <result pre="concentration at the highest vector doses in mice [22]. High" exact="systemic" post="AAV-mAb expression levels have been observed in macaques that"/>
 <result pre="(reviewed in Ref. [23]). However, it was observed that these" exact="viral" post="vectors were limited to single-use delivery, as natural serology"/>
 <result pre="[23]). However, it was observed that these viral vectors were" exact="limited" post="to single-use delivery, as natural serology and vector-induced neutralizing"/>
 <result pre="utilizing IM delivery. IV delivery is less targeted, resulting in" exact="viral" post="vector delivery and production in multiple tissues, including liver,"/>
 <result pre="of delivery continue to be important. Nevertheless, the data with" exact="viral" post="vectors, particularly AAV-mAbs, are promising and supportive of the"/>
 <result pre="and administration in resource-limited settings. One dramatic difference compared with" exact="viral" post="delivery is that synthetic DNA does not induce anti-vector"/>
 <result pre="immunoglobulin G (IgG) [36–41]. Long-term small animal studies show the" exact="total" post="duration of pDNA-mAb expression to be at least 1"/>
 <result pre="at least 1 year [42, 43]. However, in contrast to" exact="viral" post="vectors, synthetic DNA requires an efficient delivery system. By"/>
 <result pre="repeat administrations are required for long-term delivery, due to its" exact="short" post="half-life [49]. Synthetic in vitro-transcribed (IVT) mRNA is more"/>
 <result pre="being advanced to enhance translation and stability, as well as" exact="lower" post="innate inflammation via many of the innate immune sensors"/>
 <result pre="of the innate immune sensors (reviewed in Ref. [48]). The" exact="limited" post="studies of mRNA in the clinic have shown some"/>
 <result pre="[53–55]. In contrast to mRNA, supercoiled plasmid DNA drives more" exact="limited" post="innate stimulation of cytosolic DNA sensors (STING, c-GAS, and"/>
 <result pre="mRNA, supercoiled plasmid DNA drives more limited innate stimulation of" exact="cytosolic" post="DNA sensors (STING, c-GAS, and TBK1) [56–58] and activation"/>
 <result pre="progress. The safety data to date for both non-viral and" exact="viral" post="vectors have been established from vaccine and gene therapy"/>
 <result pre="will be informative as the field moves forward (NCT03831503, NCT03829384)." exact="Viral" post="vectors have mostly been focused in the area of"/>
 <result pre="Viral vectors have mostly been focused in the area of" exact="disease" post="therapy, with few studies in normal healthy humans for"/>
 <result pre="studies in normal healthy humans for gene therapy. In a" exact="limited" post="number of studies, adverse events, including lymphopenia and neutropenia,"/>
 <result pre="therapy. In a limited number of studies, adverse events, including" exact="lymphopenia" post="and neutropenia, among others, have been reported for Ad"/>
 <result pre="by AAV vectors [61–64], potentially resulting in permanent rather than" exact="transient" post="gene transfer. Such integration events are still unpredictable and"/>
 <result pre="and require additional study to further elucidate. Higher doses of" exact="viral" post="vector may circumvent pre-existing immunity; however, toxicity has been"/>
 <result pre="importance of this approach. However, the utility of AAV for" exact="systemic" post="delivery has continued to show challenges, with anti-vector immune"/>
 <result pre="of an mRNA-rabies vaccine [55]. The afflicted individual presented with" exact="transient" post="Bell’s palsy, recovering after a second vaccination. Vaccine studies"/>
 <result pre="understanding of RNA retrotransposons through long interspersed element (LINE) and" exact="short" post="interspersed element (SINE) processes has informed much about the"/>
 <result pre="platform is theoretical, which is not the case for many" exact="viral" post="vectors. A survey of integration historical events in the"/>
 <result pre="which results in the abrogation of genetic functionality in somatic" exact="neuronal" post="development [75]. Undoubtedly, these studies highlight the complexity and"/>
 <result pre="well-tolerated, with only mild-to-moderate local (injection site) reactogenicity and no" exact="systemic" post="toxicity observed in the thousands of persons studied, irrespective"/>
 <result pre="include the numerous human trials evaluating plasmid DNA vaccines against" exact="infectious diseases" post="in normal healthy persons. The theoretical possibility for plasmid"/>
 <result pre="genome insertion. This machinery is unlikely to be available in" exact="adult" post="human cells. This is clearly unlike the LINE and"/>
 <result pre="of in vivo expression. While long-lasting expression of antibodies targeting" exact="infectious" post="pathogens is unlikely to be problematic, prolonged expression of"/>
 <result pre="as on/off switches would be useful. Gene therapy studies with" exact="viral" post="vectors have previously considered herpes simplex virus thymidine kinase"/>
 <result pre="useful. Gene therapy studies with viral vectors have previously considered" exact="herpes" post="simplex virus thymidine kinase (HSV-tk) as a potential &quot;suicide�?"/>
 <result pre="and is not active in non-dividing cells such as skeletal" exact="muscle" post="[82, 83]. Alternatively, the inducible caspase-9 system (iCasp9) has"/>
 <result pre="However, dasatinib has been shown to be toxic in skeletal" exact="muscle" post="cells [89]. Furthermore, dasatinib does not completely remove CAR-T"/>
 <result pre="CAR-T fields, additional study of gene safety switches in skeletal" exact="muscle" post="would be useful for pDNA-mAb platforms. Recently, the first"/>
 <result pre="of an anti-Zika virus DNA-encoded mAb (DMAb) (NCT03831503, estimated to" exact="complete" post="in early 2021) has opened. This study will provide"/>
 <result pre="in the Fc region that will increase interactions with the" exact="neonatal" post="Fc receptor (FcRn) [104]. These modifications include M252Y/S254T/T256E (YTE)"/>
 <result pre="mouse models would be highly informative for both non-viral and" exact="viral" post="delivery and provide an important path forward for preclinical"/>
 <result pre="path forward for preclinical evaluation of in vivo-delivered antibodies [109]." exact="Cancer" post="Immunotherapy The first clinically relevant mAb approved by the"/>
 <result pre="first successful mAb therapy approved for the treatment of hematological" exact="B-cell lymphoma" post="[113]. Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) are two of"/>
 <result pre="successful mAb therapy approved for the treatment of hematological B-cell" exact="lymphoma" post="[113]. Nivolumab (anti-PD1) and ipilimumab (anti-CTLA4) are two of"/>
 <result pre="and have clinically been shown to increase overall survival and" exact="tumor" post="progression for inoperable metastatic melanoma. According to the first-quarter"/>
 <result pre="shown to increase overall survival and tumor progression for inoperable" exact="metastatic" post="melanoma. According to the first-quarter average sales prices for"/>
 <result pre="US$153, respectively [114]. For an 80-kg, stage III or higher" exact="melanoma" post="patient, a combination regimen of nivolumab and ipilimumab prescribes"/>
 <result pre="combination treatment alone amounts to about US$300,000 a year in" exact="total" post="overall treatment, not accounting for other point-of-care measure costs"/>
 <result pre="an anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse" exact="prostate cancer" post="model [116]. In vivo, their study showed expression for"/>
 <result pre="anti-prostate-specific membrane antigen (anti-PSMA) encoded DNA in a mouse prostate" exact="cancer" post="model [116]. In vivo, their study showed expression for"/>
 <result pre="days post-injection, with important anti-tumor functionality, as tumor-challenged mice exhibited" exact="tumor" post="regression and greater than 80% survival 58 days post-challenge"/>
 <result pre="anti-PSMA DMAb and challenged were significantly less able to clear" exact="tumor" post="and had less than 10% viability after a 56-day"/>
 <result pre="only target and shrink specific tumors and those in hematological" exact="cancer" post="models in vivo, but they can have a survival"/>
 <result pre="DMAb-encoded anti-human CTLA4 ipilimumab and tremelimumab in vitro using donor-derived" exact="peripheral" post="blood mononuclear cells (PBMCs) co-incubated with two different luciferase-expressing"/>
 <result pre="blood mononuclear cells (PBMCs) co-incubated with two different luciferase-expressing lymphoblast" exact="cancer" post="models and showed a dose-dependent blockage of CTLA4, leading"/>
 <result pre="is demonstrating greater efficacy in combination, prolonging overall survival in" exact="melanoma" post="patients [117]. Therefore, pDNA-mAb delivery of checkpoint inhibitors is"/>
 <result pre="early mouse studies are supportive for continued development of high" exact="cancer" post="value targets. Such developments provide opportunities to broaden the"/>
 <result pre="that receive such high-cost therapies. Cancer: Outlook As the pDNA-mAb" exact="cancer" post="approach continues through preclinical studies, new complementary applications are"/>
 <result pre="in the clinic for bringing T cells into proximity with" exact="tumor" post="surface antigens. Blinatumomab is the first BiTE antibody approved"/>
 <result pre="first BiTE antibody approved by the FDA. It targets hematological" exact="acute lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
 <result pre="BiTE antibody approved by the FDA. It targets hematological acute" exact="lymphoblastic leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
 <result pre="antibody approved by the FDA. It targets hematological acute lymphoblastic" exact="leukemia" post="by binding to both CD3 T-cell coreceptor and the"/>
 <result pre="leukemia by binding to both CD3 T-cell coreceptor and the" exact="malignant" post="B-cell CD19 antigen. This antibody allows for contact-dependent activation"/>
 <result pre="blinatumomab is highly promising in people, the BiTE has a" exact="short" post="half-life of approximately 2 h. The current regimen requires"/>
 <result pre="a plasmid-encoded delivered BiTE would undoubtedly improve upon the relative" exact="short" post="expression time length and could significantly lower the cost"/>
 <result pre="upon the relative short expression time length and could significantly" exact="lower" post="the cost of such an important treatment. Building on"/>
 <result pre="(DBTE) that binds to CD3 T cells and the Her2" exact="tumor" post="target [119]. This study demonstrated consistent in vivo expression"/>
 <result pre="for approximately 4 months, with potent functional activity showing 8/10" exact="tumor" post="regression/clearance in mice &amp;gt; 40 days after tumor challenge. Stadler et"/>
 <result pre="functional activity showing 8/10 tumor regression/clearance in mice &amp;gt; 40 days after" exact="tumor" post="challenge. Stadler et al. encoded a similar bispecific antibody"/>
 <result pre="encoding the tumor-associated antigen claudin, a tight junction protein and" exact="epithelial" post="cell adhesion molecule (EpCAM), which is overexpressed in colorectal,"/>
 <result pre="µg/kg of recombinant CD3 and claudin protein had comparable median" exact="tumor" post="volume. The mRNA-encoded bispecific antibody showed earlier and rapid"/>
 <result pre="tumor volume. The mRNA-encoded bispecific antibody showed earlier and rapid" exact="tumor" post="regression, with fewer overall doses. Overall, both mRNA-encoded bispecific"/>
 <result pre="approaches offer the ability to harness T-cell functionality in blocking" exact="tumor" post="antigen function and initiating potent cytotoxicity, but vary in"/>
 <result pre="These are interesting and promising and likely complementary strategies for" exact="cancer" post="immunotherapy that deserve significant attention. Infectious Disease Control There"/>
 <result pre="likely complementary strategies for cancer immunotherapy that deserve significant attention." exact="Infectious" post="Disease Control There is tremendous potential for mAb delivery"/>
 <result pre="complementary strategies for cancer immunotherapy that deserve significant attention. Infectious" exact="Disease" post="Control There is tremendous potential for mAb delivery to"/>
 <result pre="potential for mAb delivery to have an impact in the" exact="infectious diseases" post="arena. Through advancements in antibody discovery technologies, highly specific"/>
 <result pre="humans with activity against anti-microbial resistant bacteria, emerging and re-emerging" exact="viral" post="pathogens, and parasitic and fungal diseases. Yet, palivizumab (Synagis),"/>
 <result pre="successful mAb approved as a standalone intervention to prevent an" exact="infectious disease." post="Synagis costs can be &amp;gt; US$12,000 for a five-dose (15 mg/kg/dose)"/>
 <result pre="2016 and is indicated to reduce recurrence of C. difficile" exact="infection" post="(CDI) in patients 18 years of age or older"/>
 <result pre="raxibacumab and obiltoxaximab, have been approved for treatment of inhalational" exact="anthrax" post="via the FDA Animal Efficacy Rule. The Animal Rule"/>
 <result pre="remain important obstacles that impede administration for the treatment of" exact="infectious diseases." post="Current antibody limitations impede widespread delivery for seasonal outbreaks"/>
 <result pre="and epidemics for influenza viruses. Repeat doses are required to" exact="lower" post="HIV viral loads. The development and manufacturing timeline for"/>
 <result pre="for influenza viruses. Repeat doses are required to lower HIV" exact="viral" post="loads. The development and manufacturing timeline for rapid response"/>
 <result pre="The development and manufacturing timeline for rapid response to emerging" exact="infectious disease" post="outbreaks, for example, Ebolavirus, is long and requires cold-chain"/>
 <result pre="development and manufacturing timeline for rapid response to emerging infectious" exact="disease" post="outbreaks, for example, Ebolavirus, is long and requires cold-chain"/>
 <result pre="antibody delivery represents an attractive approach for antibody administration targeting" exact="infectious diseases." post="Viral Infections and Speed to Intervention Both DNA- and"/>
 <result pre="represents an attractive approach for antibody administration targeting infectious diseases." exact="Viral" post="Infections and Speed to Intervention Both DNA- and mRNA-mAbs"/>
 <result pre="an attractive approach for antibody administration targeting infectious diseases. Viral" exact="Infections" post="and Speed to Intervention Both DNA- and mRNA-mAbs represent"/>
 <result pre="DNA- and mRNA-mAbs represent potential rapid delivery platforms for emerging" exact="infectious disease" post="control. Both platforms start with initial antigen-specific mAb sequence"/>
 <result pre="and mRNA-mAbs represent potential rapid delivery platforms for emerging infectious" exact="disease" post="control. Both platforms start with initial antigen-specific mAb sequence"/>
 <result pre="batches, and is ready for in vivo delivery within a" exact="short" post="timeline (Fig. 5). The process for mRNA-mAb development is"/>
 <result pre="for mRNA-mAb development is similar, but requires additional manufacturing steps." exact="Antibody" post="sequences are engineered into a DNA plasmid that includes"/>
 <result pre="37, 97], Ebolavirus [36, 42], Zika virus [38], CHIKV [121]," exact="rabies" post="[15], and HIV [49]. Anti-Dengue Virus pDNA-mAbs Close to"/>
 <result pre="billion people are estimated to be at risk for dengue" exact="virus infection" post="worldwide, mostly in developing countries and in resource-poor settings"/>
 <result pre="people are estimated to be at risk for dengue virus" exact="infection" post="worldwide, mostly in developing countries and in resource-poor settings"/>
 <result pre="the LALA mutation into the Fc region to mitigate dengue" exact="secondary" post="infection. The anti-dengue virus DMAb achieved peak expression levels"/>
 <result pre="Both the anti-dengue virus wt-DMAb and LALA-DMAb demonstrated protection against" exact="primary" post="dengue infection. The LALA-DMAb demonstrated protection against dengue virus"/>
 <result pre="primary dengue infection. The LALA-DMAb demonstrated protection against dengue virus" exact="primary" post="infection, as well as protection in a mouse model"/>
 <result pre="in a mouse model of antibody-dependent enhancement that models dengue" exact="secondary" post="infection. Overall, this demonstrates the portability of traditional mAb"/>
 <result pre="engineering strategies to pDNA-mAb platforms for unique strategies against emerging" exact="viral" post="infections. Anti-influenza Virus pDNA-mAbs An estimated 45 million people"/>
 <result pre="delivery could have an important impact on lowering overall influenza" exact="disease" post="burden during seasonal influenza epidemics and against potential pandemic"/>
 <result pre="showed the benefit of delivery and hyaluronidase pre-treatment of the" exact="muscle" post="to increase muscle uptake of DNA, resulting in serum"/>
 <result pre="of delivery and hyaluronidase pre-treatment of the muscle to increase" exact="muscle" post="uptake of DNA, resulting in serum levels of &amp;gt; 15 μg/mL"/>
 <result pre="Similarly, anti-B/HA DMAbs protected against both B/Yamagata and B/Victoria lineage" exact="virus infection" post="in mice. Additionally, a combination of both anti-A/HA and"/>
 <result pre="anti-B/HA DMAbs protected against both B/Yamagata and B/Victoria lineage virus" exact="infection" post="in mice. Additionally, a combination of both anti-A/HA and"/>
 <result pre="influenza A and B viruses. Anti-ebolavirus pDNA-mAbs The 2013–2016 Ebolavirus" exact="disease" post="(EVD) epidemic was the largest to date, with over"/>
 <result pre="Congo, and additional gene-encoded alternatives could be useful for EVD" exact="infection" post="control to support post-exposure vaccines and therapeutics. Antibodies against"/>
 <result pre="only 8 days before lethal challenge and also provide long-term" exact="partial" post="protection when challenged 82 days post-administration. These studies are"/>
 <result pre="pDNA-mAbs Over 2 billion people are at risk for Zika" exact="virus infection" post="[125]. Building on the early studies with the anti-dengue"/>
 <result pre="Over 2 billion people are at risk for Zika virus" exact="infection" post="[125]. Building on the early studies with the anti-dengue"/>
 <result pre="of challenge, and four out of five animals controlled Zika" exact="virus infection." post="This was the first demonstration that a nucleic acid-encoded"/>
 <result pre="first demonstration that a nucleic acid-encoded antibody can control an" exact="infectious disease" post="challenge in a larger animal model, further supporting translation"/>
 <result pre="demonstration that a nucleic acid-encoded antibody can control an infectious" exact="disease" post="challenge in a larger animal model, further supporting translation"/>
 <result pre="living with HIV, with the envelope GP (Env) being the" exact="primary" post="target for immune responses. Due to the high diversity"/>
 <result pre="significant in vivo expression level using pDNA-mAb platforms. mRNA-mAbs Targeting" exact="Infectious" post="Diseases To date, mRNA-mAbs, formulated in LNP, have been"/>
 <result pre="in vivo expression level using pDNA-mAb platforms. mRNA-mAbs Targeting Infectious" exact="Diseases" post="To date, mRNA-mAbs, formulated in LNP, have been evaluated"/>
 <result pre="To date, mRNA-mAbs, formulated in LNP, have been evaluated targeting" exact="rabies" post="[15], HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin"/>
 <result pre="HIV [49], and CHIKV [127]. Human anti-rabies immunoglobulin and the" exact="rabies" post="vaccine must be delivered immediately following potential rabies exposure."/>
 <result pre="and the rabies vaccine must be delivered immediately following potential" exact="rabies" post="exposure. Thran et al. evaluated an mRNA-mAb platform for"/>
 <result pre="pre-exposure (day − 1) and post-exposure (2 h post-infection) protection against lethal" exact="rabies" post="virus challenge in mice. In this study, an anti-influenza"/>
 <result pre="CHIKV. They demonstrated dose-dependent protection against the virus, with no" exact="viral" post="load and protection against arthritis and muscoskeletal disease in"/>
 <result pre="against the virus, with no viral load and protection against" exact="arthritis" post="and muscoskeletal disease in competent C57BL6 mice [127]. They"/>
 <result pre="with no viral load and protection against arthritis and muscoskeletal" exact="disease" post="in competent C57BL6 mice [127]. They further evaluated expression"/>
 <result pre="the platform to make it more accessible in low-resource settings." exact="Bacterial Infections" post="Antibodies are promising for control of antimicrobial resistant organisms"/>
 <result pre="platform to make it more accessible in low-resource settings. Bacterial" exact="Infections" post="Antibodies are promising for control of antimicrobial resistant organisms"/>
 <result pre="promising for control of antimicrobial resistant organisms and other serious" exact="bacterial infections." post="Each year, at least two million people acquire antimicrobial"/>
 <result pre="100 days. This DMAb targeted two P. aeruginosa proteins (PcrV" exact="type III" post="secretion system and Psl exopolysaccharide), protecting against lethal pneumonia"/>
 <result pre="type III secretion system and Psl exopolysaccharide), protecting against lethal" exact="pneumonia" post="in a mouse challenge model. Lower levels of pro-inflammatory"/>
 <result pre="to protect against ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae," exact="Acinetobacter" post="baumannii, Pseudomonas aeruginosa, Enterobacter species) pathogens and other resistant"/>
 <result pre="and other resistant bacteria have the potential to dramatically impact" exact="infection" post="control and the spread of anti-microbial resistance in both"/>
 <result pre="in both hospital and community settings. Around 30,000 cases of" exact="Lyme disease" post="are reported each year to the US Centers for"/>
 <result pre="both hospital and community settings. Around 30,000 cases of Lyme" exact="disease" post="are reported each year to the US Centers for"/>
 <result pre="disease are reported each year to the US Centers for" exact="Disease" post="Control (CDC); however, it is likely that the actual"/>
 <result pre="supports the potential for a DMAb approach to protect against" exact="Lyme disease" post="transmission from tick to host. To date, the only"/>
 <result pre="the potential for a DMAb approach to protect against Lyme" exact="disease" post="transmission from tick to host. To date, the only"/>
 <result pre="tick to host. To date, the only mRNA-mAb targeting a" exact="bacterial" post="pathogen is against botulinum toxin A1 [15]. Botulism is"/>
 <result pre="targeting a bacterial pathogen is against botulinum toxin A1 [15]." exact="Botulism" post="is caused by the toxin from Clostridium botulinum and"/>
 <result pre="h post-exposure. Additional development of mRNA-mAbs for rapid delivery against" exact="bacterial" post="toxins that require protection within hours of exposure has"/>
 <result pre="within hours of exposure has the potential to be important." exact="Infectious" post="Diseases: Outlook pDNA-mAb platforms can be utilized to rapidly"/>
 <result pre="nucleic acid biologics, including the National Institutes of Health, Defense" exact="Advanced" post="Research Projects Agency (DARPA), Biomedical Advanced Research and Development"/>
 <result pre="Institutes of Health, Defense Advanced Research Projects Agency (DARPA), Biomedical" exact="Advanced" post="Research and Development Authority (BARDA), and the Bill and"/>
 <result pre="comparison, there are much fewer studies with mRNA-mAb delivery against" exact="infectious diseases." post="As the field advances, it will be important to"/>
 <result pre="al. evaluated plasmid DNA delivery of an anti-idiotype antibody targeting" exact="B-cell lymphoma," post="observing modest anti-tumor activity [131]. However, this study did"/>
 <result pre="µg/mL (summary of data from non-human primates receiving 2–9 mg" exact="total" post="DNA in 4–6 injection sites) (Fig. 7, magenta), and"/>
 <result pre="further increases, now to levels &amp;gt; 30 µg/mL (6 mg" exact="total" post="DNA injection, six injections), which express for 35 days"/>
 <result pre="inset) Dose scaling is an important consideration for non-viral and" exact="viral" post="vector-encoded antibodies. Plasmid DNA is transiently transfected into muscle"/>
 <result pre="and viral vector-encoded antibodies. Plasmid DNA is transiently transfected into" exact="muscle" post="and may persist in the tissue for a few"/>
 <result pre="may persist in the tissue for a few weeks. Likewise," exact="viral" post="vectors typically persist in tissues for a few months,"/>
 <result pre="was detected in participants’ sera, although PG9 was detected in" exact="muscle" post="biopsies. One possibility for the lack of detection is"/>
 <result pre="life for many individuals. However, use has been restricted to" exact="disease" post="populations with high commercial value, due in part to"/>
 <result pre="Other modifications including half-life extension to improve interactions with the" exact="neonatal" post="FcRs and glycosylation profiles would be highly informative for"/>
 <result pre="opening a new direction in the field that was previously" exact="limited" post="to biologics, with powerful potential applications for in vivo"/>
 <result pre="development of biologics, opening up new areas of opportunity for" exact="disease" post="treatments of global importance for patients and for animal"/>
 <result pre="References 1.BrinkmannUKontermannREThe making of bispecific antibodiesMAbs20179218221210.1080/19420862.2016.126830728071970 2.VoigtASemenovaTYamamotoJEtienneVNguyenCQTherapeutic antibody discovery in" exact="infectious diseases" post="using single-cell analysisAdv Exp Med Biol201810688910210.1007/978-981-13-0502-3_829943298 3.BradburyARSidhuSDubelSMcCaffertyJBeyond natural antibodies:"/>
 <result pre="Ther Methods Clin Dev201888710410.1016/j.omtm.2017.11.00729326962 15.ThranMMukherjeeJPonischMFiedlerKThessAMuiBLet al.mRNA mediates passive vaccination against" exact="infectious" post="agents, toxins, and tumorsEMBO Mol Med20179101434144710.15252/emmm.20170767828794134 16.NasoMFTomkowiczBPerryWL3rdStrohlWRAdeno-associated virus (AAV)"/>
 <result pre="21.SkaricicDTraubeCDeBJohJBoyerJCrystalRGet al.Genetic delivery of an anti-RSV antibody to protect against" exact="pulmonary" post="infection with RSVVirology20083781798510.1016/j.virol.2008.04.01618556039 22.BalazsABChenJHongCMRaoDSYangLBaltimoreDAntibody-based protection against HIV infection by"/>
 <result pre="al.Genetic delivery of an anti-RSV antibody to protect against pulmonary" exact="infection" post="with RSVVirology20083781798510.1016/j.virol.2008.04.01618556039 22.BalazsABChenJHongCMRaoDSYangLBaltimoreDAntibody-based protection against HIV infection by vectored"/>
 <result pre="to protect against pulmonary infection with RSVVirology20083781798510.1016/j.virol.2008.04.01618556039 22.BalazsABChenJHongCMRaoDSYangLBaltimoreDAntibody-based protection against" exact="HIV infection" post="by vectored immunoprophylaxisNature20114817379818410.1038/nature1066022139420 23.LinABalazsABAdeno-associated virus gene delivery of broadly"/>
 <result pre="protect against pulmonary infection with RSVVirology20083781798510.1016/j.virol.2008.04.01618556039 22.BalazsABChenJHongCMRaoDSYangLBaltimoreDAntibody-based protection against HIV" exact="infection" post="by vectored immunoprophylaxisNature20114817379818410.1038/nature1066022139420 23.LinABalazsABAdeno-associated virus gene delivery of broadly"/>
 <result pre="antibody mediates significant protective effects against SIVmac239 challenge in the" exact="absence of" post="neutralizing activityPLoS Pathog2015118e100509010.1371/journal.ppat.100509026248318 25.AdamVSCrosariolMKumarSGeMQCzackSERoySet al.Adeno-associated virus 9-mediated airway expression"/>
 <result pre="of the broadly neutralizing antibody FI6 in mouse airway provides" exact="partial" post="protection against a new avian influenza A virus, H7N9Clin"/>
 <result pre="FI6 in mouse airway provides partial protection against a new" exact="avian influenza" post="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against"/>
 <result pre="A virus, H7N9Clin Vaccine Immunol201320121836183710.1128/CVI.00545-1324132603 28.LaursenNSFriesenRHEZhuXJongeneelenMBloklandSVermondJet al.Universal protection against influenza" exact="infection" post="by a multidomain antibody to influenza hemagglutininScience2018362641459860210.1126/science.aaq062030385580 29.LimberisMPTretiakovaANambiarKWongGRacineTCrosariolMet al.Adeno-associated"/>
 <result pre="al.Adeno-associated virus serotype 9-expressed ZMapp in mice confers protection against" exact="systemic" post="and airway-acquired Ebola virus infectionJ Infect Dis2016214121975197910.1093/infdis/jiw46027683818 30.RobertMANassouryNChahalPSVenneMHRacineTQiuXet al.Gene"/>
 <result pre="Ther201829445246610.1089/hum.2017.10129179602 31.SantryLAIngraoJCYuDLde JongJGvan LieshoutLPWoodGAet al.AAV vector distribution in the mouse" exact="respiratory" post="tract following four different methods of administrationBMC Biotechnol20171714310.1186/s12896-017-0365-228506256 32.McNamaraMANairSKHollEKRNA-based"/>
 <result pre="following four different methods of administrationBMC Biotechnol20171714310.1186/s12896-017-0365-228506256 32.McNamaraMANairSKHollEKRNA-based vaccines in" exact="cancer" post="immunotherapyJ Immunol Res2015201579452810.1155/2015/79452826665011 33.JulianoRAlamMRDixitVKangHMechanisms and strategies for effective delivery"/>
 <result pre="bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a" exact="pneumonia" post="challenge modelNat Commun20178163710.1038/s41467-017-00576-728935938 40.HollevoetKDe VleeschauwerSDe SmidtEVermeireGGeukensNDeclerckPBridging the clinical gap"/>
 <result pre="delivery of synthetic human DNA-encoded monoclonal antibodies protect against Ebolavirus" exact="infection" post="in a mouse modelCell Rep.20182571982199310.1016/j.celrep.2018.10.06230428362 43.WiseMCXuZTello-RuizEBeckCTrautzAPatelAet al.In vivo delivery"/>
 <result pre="Opin Immunol201123342142910.1016/j.coi.2011.03.00821530212 45.ModjarradKRobertsCCMillsKTCastellanoARPaolinoKMuthumaniKet al.Safety and immunogenicity of an anti-Middle East" exact="respiratory" post="syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm,"/>
 <result pre="Immunol201123342142910.1016/j.coi.2011.03.00821530212 45.ModjarradKRobertsCCMillsKTCastellanoARPaolinoKMuthumaniKet al.Safety and immunogenicity of an anti-Middle East respiratory" exact="syndrome" post="coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation"/>
 <result pre="Dis20191991013102210.1016/S1473-3099(19)30266-X31351922 46.TebasPKraynyakKAPatelAMaslowJNMorrowMPSylvesterAJet al.Intradermal SynCon(R) Ebola GP DNA vaccine is temperature" exact="stable" post="and safely demonstrates cellular and humoral immunogenicity advantages in"/>
 <result pre="vaccine—preliminary reportN Engl J Med201710.1056/NEJMoa170812028976850 48.ZhangCMaruggiGShanHLiJAdvances in mRNA vaccines for" exact="infectious" post="diseasesFront Immunol20191059410.3389/fimmu.2019.0059430972078 49.PardiNSecretoAJShanXDeboneraFGloverJYiYet al.Administration of nucleoside-modified mRNA encoding broadly"/>
 <result pre="influenza virusesMol Ther20172561316132710.1016/j.ymthe.2017.03.03528457665 55.AlbererMGnad-VogtUHongHSMehrKTBackertLFinakGet al.Safety and immunogenicity of a mRNA" exact="rabies" post="vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human"/>
 <result pre="prospective, first-in-human phase 1 clinical trialLancet2017390101011511152010.1016/S0140-6736(17)31665-328754494 56.IshikawaHMaZBarberGNSTING regulates intracellular DNA-mediated," exact="type I" post="interferon-dependent innate immunityNature2009461726578879210.1038/nature0847619776740 57.WuJSunLChenXDuFShiHChenCet al.Cyclic GMP-AMP is an endogenous"/>
 <result pre="is an endogenous second messenger in innate immune signaling by" exact="cytosolic" post="DNAScience2013339612182683010.1126/science.122996323258412 58.IshiiKJKawagoeTKoyamaSMatsuiKKumarHKawaiTet al.TANK-binding kinase-1 delineates innate and adaptive immune"/>
 <result pre="but functions in TLR9-deficient miceJ Immunol2003171115908591210.4049/jimmunol.171.11.590814634101 60.ReidTWarrenRKirnDIntravascular adenoviral agents in" exact="cancer" post="patients: lessons from clinical trialsCancer Gene Ther200291297998610.1038/sj.cgt.770053912522437 61.ZhongLMalaniNLiMBradyTXieJBellPet al.Recombinant"/>
 <result pre="of Health Recombinant DNA Advisory CommitteeMol Genet Metab200213131310.1089/10430340152712629 68.RaperSEChirmuleNLeeFSWivelNABaggAGaoGPet al.Fatal" exact="systemic" post="inflammatory response syndrome in a ornithine transcarbamylase deficient patient"/>
 <result pre="DNA Advisory CommitteeMol Genet Metab200213131310.1089/10430340152712629 68.RaperSEChirmuleNLeeFSWivelNABaggAGaoGPet al.Fatal systemic inflammatory response" exact="syndrome" post="in a ornithine transcarbamylase deficient patient following adenoviral gene"/>
 <result pre="al.Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola," exact="Severe" post="Acute Respiratory Syndrome, or West Nile virus is similar"/>
 <result pre="safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe" exact="Acute" post="Respiratory Syndrome, or West Nile virus is similar despite"/>
 <result pre="evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute" exact="Respiratory" post="Syndrome, or West Nile virus is similar despite differing"/>
 <result pre="Sci200691262063010.1093/toxsci/kfj17016569728 78.SheetsRLSteinJManetzTSDuffyCNasonMAndrewsCet al.Biodistribution of DNA plasmid vaccines against HIV-1, Ebola," exact="Severe" post="Acute Respiratory Syndrome, or West Nile virus is similar,"/>
 <result pre="78.SheetsRLSteinJManetzTSDuffyCNasonMAndrewsCet al.Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe" exact="Acute" post="Respiratory Syndrome, or West Nile virus is similar, without"/>
 <result pre="al.Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute" exact="Respiratory" post="Syndrome, or West Nile virus is similar, without integration,"/>
 <result pre="kinase/ganciclovir-mediated apoptotic death of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of" exact="cancer" post="cells by herpes simplex virus thymidine kinase gene is"/>
 <result pre="of bystander cellsCancer Res19965612269727028665496 83.MesnilMPiccoliCTirabyGWilleckeKYamasakiHBystander killing of cancer cells by" exact="herpes" post="simplex virus thymidine kinase gene is mediated by connexinsProc"/>
 <result pre="safety of allodepleted T cells after haploidentical stem cell transplantationBiol" exact="Blood" post="Marrow Transplant200713891392410.1016/j.bbmt.2007.04.00517640595 86.StavrouMPhilipBTraynor-WhiteCDavisCGOnuohaSCordobaSet al.A rapamycin-activated caspase 9-based suicide geneMol"/>
 <result pre="on/off switch for CAR T cellsSci Transl Med201910.1126/scitranslmed.aau5907 89.JanssenLFrambachSAllardNAEHopmanMTESchirrisTJJVoermansNCet al.Skeletal" exact="muscle" post="toxicity associated with tyrosine kinase inhibitor therapy in patients"/>
 <result pre="toxicity associated with tyrosine kinase inhibitor therapy in patients with" exact="chronic" post="myeloid leukemiaLeukemia20193382116212010.1038/s41375-019-0443-730872782 90.BarrettJACaiHMiaoJKharePDGonzalezPDalsing-HernandezJet al.Regulated intratumoral expression of IL-12 using"/>
 <result pre="Gene Ther2018255–610611610.1038/s41417-018-0019-029755109 91.ChioccaEAYuJSLukasRVSolomonIHLigonKLNakashimaHet al.Regulatable interleukin-12 gene therapy in patients with" exact="recurrent" post="high-grade glioma: results of a phase 1 trialSci Transl"/>
 <result pre="gene therapy promoter systemHealthy Subj Clin Pharmacol Drug Dev20176324625710.1002/cpdd.287 93.PerezNBigeyPSchermanDDanosOPiechaczykMPelegrinMRegulatable" exact="systemic" post="production of monoclonal antibodies by in vivo muscle electroporationGenet"/>
 <result pre="Dev20176324625710.1002/cpdd.287 93.PerezNBigeyPSchermanDDanosOPiechaczykMPelegrinMRegulatable systemic production of monoclonal antibodies by in vivo" exact="muscle" post="electroporationGenet Vaccines Ther200421210.1186/1479-0556-2-215038826 94.TjelleTECorthayALundeESandlieIMichaelsenTEMathiesenIet al.Monoclonal antibodies produced by muscle"/>
 <result pre="vivo muscle electroporationGenet Vaccines Ther200421210.1186/1479-0556-2-215038826 94.TjelleTECorthayALundeESandlieIMichaelsenTEMathiesenIet al.Monoclonal antibodies produced by" exact="muscle" post="after plasmid injection and electroporationMol Ther20049332833610.1016/j.ymthe.2003.12.00715006599 95.AkerstromTVedelKNeedhamJHojmanPKontouEHellstenYet al.Optimizing hyaluronidase"/>
 <result pre="muscleBiochem Biophys Rep2015434235010.1016/j.bbrep.2015.10.00729124223 96.McMahonJMSignoriEWellsKEFazioVMWellsDJOptimisation of electrotransfer of plasmid into skeletal" exact="muscle" post="by pretreatment with hyaluronidase—increased expression with reduced muscle damageGene"/>
 <result pre="into skeletal muscle by pretreatment with hyaluronidase—increased expression with reduced" exact="muscle" post="damageGene Ther20018161264127010.1038/sj.gt.330152211509960 97.YamazakiTNagashimaMNinomiyaDAraiYTeshimaYFujimotoAet al.Passive immune-prophylaxis against influenza virus infection"/>
 <result pre="with reduced muscle damageGene Ther20018161264127010.1038/sj.gt.330152211509960 97.YamazakiTNagashimaMNinomiyaDAraiYTeshimaYFujimotoAet al.Passive immune-prophylaxis against influenza" exact="virus infection" post="by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from"/>
 <result pre="reduced muscle damageGene Ther20018161264127010.1038/sj.gt.330152211509960 97.YamazakiTNagashimaMNinomiyaDAraiYTeshimaYFujimotoAet al.Passive immune-prophylaxis against influenza virus" exact="infection" post="by the expression of neutralizing anti-hemagglutinin monoclonal antibodies from"/>
 <result pre="100.DuperretEKTrautzAStoltzRPatelAWiseMCPerales-PuchaltAet al.Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces" exact="tumor" post="shrinkage in vivoCancer Res201878226363637010.1158/0008-5472.CAN-18-142930287678 101.FlingaiSPlummerEMPatelAShrestaSMendozaJMBroderickKEet al.Protection against dengue disease"/>
 <result pre="antibodies induces tumor shrinkage in vivoCancer Res201878226363637010.1158/0008-5472.CAN-18-142930287678 101.FlingaiSPlummerEMPatelAShrestaSMendozaJMBroderickKEet al.Protection against" exact="dengue disease" post="by synthetic nucleic acid antibody prophylaxis/immunotherapySci Rep201551261610.1038/srep1261626220099 102.Perales-PuchaltADuperretEKMuthumaniKWeinerDBSimplifying checkpoint"/>
 <result pre="induces tumor shrinkage in vivoCancer Res201878226363637010.1158/0008-5472.CAN-18-142930287678 101.FlingaiSPlummerEMPatelAShrestaSMendozaJMBroderickKEet al.Protection against dengue" exact="disease" post="by synthetic nucleic acid antibody prophylaxis/immunotherapySci Rep201551261610.1038/srep1261626220099 102.Perales-PuchaltADuperretEKMuthumaniKWeinerDBSimplifying checkpoint"/>
 <result pre="105.Dall'AcquaWFKienerPAWuHProperties of human IgG1s engineered for enhanced binding to the" exact="neonatal" post="Fc receptor (FcRn)J Biol Chem200628133235142352410.1074/jbc.M60429220016793771 106.ZalevskyJChamberlainAKHortonHMKarkiSLeungIWSprouleTJet al.Enhanced antibody half-life"/>
 <result pre="vivo activityNat Biotechnol201028215715910.1038/nbt.160120081867 107.YeungYALeabmanMKMarvinJSQiuJAdamsCWLienSet al.Engineering human IgG1 affinity to human" exact="neonatal" post="Fc receptor: impact of affinity improvement on pharmacokinetics in"/>
 <result pre="and efficacy of antibody and antibody-drug conjugate via Fc-FcgammaR interactionMol" exact="Cancer" post="Ther201918478078710.1158/1535-7163.MCT-18-097730824607 112.SmithSLTen years of Orthoclone OKT3 (muromonab-CD3): a reviewJ"/>
 <result pre="OKT3 (muromonab-CD3): a reviewJ Transpl Coord.19966310911910.7182/prtr.1.6.3.8145l3u1854931829188368 113.BoyiadzisMFoonKAApproved monoclonal antibodies for" exact="cancer" post="therapyExpert Opin Biol Ther2008881151115810.1517/14712598.8.8.115118613766 114.Services CgCfMM. 2019 ASP drug"/>
 <result pre="Accessed 23 Nov 2019. 115.SaltzLBPerspectives on cost and value in" exact="cancer" post="careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate cancer immunotherapy with a"/>
 <result pre="on cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel" exact="prostate cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
 <result pre="cost and value in cancer careJAMA Oncol201621192110.1001/jamaoncol.2015.419126501848 116.MuthumaniKMarninLKudchodkarSBPerales-PuchaltAChoiHAgarwalSet al.Novel prostate" exact="cancer" post="immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibodyCancer"/>
 <result pre="immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against" exact="chikungunya" post="virusJ Infect Dis2016214336937810.1093/infdis/jiw11127001960 122.BradyJMBaltimoreDBalazsABAntibody gene transfer with adeno-associated viral"/>
 <result pre="against chikungunya virusJ Infect Dis2016214336937810.1093/infdis/jiw11127001960 122.BradyJMBaltimoreDBalazsABAntibody gene transfer with adeno-associated" exact="viral" post="vectors as a method for HIV preventionImmunol Rev2017275132433310.1111/imr.1247828133808 123.Prevention"/>
 <result pre="the United States—2017–2018 influenza season. In: Influenza (Flu). Centers for" exact="Disease" post="Control and Prevention, Atlanta, GA. 2019. https://www.cdc.gov/flu/about/burden/2017-2018.htm. Accessed 23"/>
 <result pre="mRNA encoding a potently neutralizing human monoclonal antibody protects against" exact="chikungunya" post="infectionSci Immunol.201910.1126/sciimmunol.aaw66476629435 128.WuXHIV broadly neutralizing antibodies: VRC01 and beyondAdv"/>
 <result pre="Biol20181075537210.1007/978-981-13-0484-2_330030789 129.Prevention CfDCa. Lyme disease: data and surveillance. Centers for" exact="Disease" post="Control and Prevention. 2019. https://www.cdc.gov/lyme/datasurveillance/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Flyme%2Fstats%2Findex.html. Accessed 14 Aug 2019."/>
</results>
